Uncategorized
GSK goes beyond weight-loss with $1B buyout of Chinese siRNA specialist
With Siran Biotechnology under its fold, GSK will have access to a long-acting siRNA therapy that could induce weight loss while preserving lean mass, in addition to addressing other weight-related comorbidities.